Core Viewpoint - Fudan Zhangjiang (01349.HK) has entered into an agreement with Bank of China to subscribe to a structured deposit product using temporarily idle funds raised from its A-share public offering, amounting to RMB 150 million [1] Group 1 - The company has agreed to invest a total of RMB 150 million in a structured deposit product [1] - The funds used for this investment are from the proceeds of the company's A-share public offering [1] - The agreement is with Bank of China, indicating a strategic partnership for financial management [1]

格隆汇1月6日丨复旦张江(01349.HK)公告，近日，公司与中国银行订立中国银行结构性存款产品协议， 同意以A股公开发行所得暂时闲置募集资金向中国银行认购总金额为人民币1.5亿元的结构性存款产品。 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1 - The core point of the news is that Qingdao Weilan Biological Co., Ltd. experienced a stock price increase of 5.02%, reaching 15.06 CNY per share, with a total market capitalization of 3.811 billion CNY [1] - The company, established on February 23, 2005, specializes in the research, production, and sales of enzyme preparations, microecology, and animal health products [1] - The revenue composition of the company includes enzyme preparations at 36.63%, animal health products at 22.60%, other businesses at 21.75%, microecology at 17.27%, and others at 1.76% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund holds a position in Weilan Biological, with its Guotai Zhongzheng Livestock Breeding ETF (159865) increasing its holdings by 673,200 shares, totaling 2.1108 million shares, which represents 0.83% of the circulating shares [2] - The Guotai Zhongzheng Livestock Breeding ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY, and has recorded a year-to-date return of 0.4% [2] - The fund manager, Liang Xing, has a tenure of 9 years and 215 days, with the fund's total asset size at 30.617 billion CNY, achieving a best return of 1112.34% during the tenure [3]

Core Viewpoint - The A-share market showed mixed performance with the Shanghai Composite Index rising over 1% in early trading, indicating positive investor sentiment despite some sector declines [1]. Market Performance - The Shanghai Composite Index closed at 4069.38 points, up 1.14% - The Shenzhen Component Index closed at 13940.24 points, up 0.81% - The ChiNext Index closed at 3293.18 points, down 0.04% [1]. Sector Performance Top Performing Sectors - Insurance sector increased by 4.91% with a total trading volume of 292.22 million hands and a net inflow of 15.55 billion - Small metals sector rose by 4.67% with a trading volume of 954.96 million hands and a net inflow of 37.26 billion - Energy metals sector gained 3.72% with a trading volume of 384.15 million hands and a net inflow of 18.67 billion [2]. Underperforming Sectors - Communication equipment sector decreased by 0.68% with a trading volume of 1889.06 million hands and a net outflow of 77.51 billion - Components sector fell by 0.65% with a trading volume of 929.90 million hands and a net outflow of 31.50 billion - Beauty care sector declined by 0.25% with a trading volume of 157.47 million hands and a net outflow of 0.42 billion [2].

Group 1 - The core point of the article highlights the recent performance of Dongbao Bio, with a stock price increase of 5.13% to 6.15 CNY per share, a trading volume of 97.52 million CNY, a turnover rate of 2.77%, and a total market capitalization of 3.651 billion CNY [1] - Dongbao Bio, established on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main business revenue composition of Dongbao Bio includes capsule business at 54.13%, gelatin series products and by-products at 37.30%, collagen business at 7.81%, organic fertilizer business at 0.53%, and other supplementary products at 0.22% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guangfa Fund has a fund that ranks among Dongbao Bio's top ten circulating shareholders, specifically Guangfa Jufeng Mixed A (270005), which entered the top ten in the third quarter with 4.5228 million shares, accounting for 0.77% of circulating shares [2] - Guangfa Jufeng Mixed A (270005) was established on December 23, 2005, with a latest scale of 3.366 billion CNY, and has achieved a year-to-date return of 1.2%, ranking 5853 out of 8816 in its category, and a one-year return of 59.59%, ranking 1201 out of 8081 [2]

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. has signed a market promotion service agreement with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. for the A group C group meningococcal polysaccharide conjugate vaccine, indicating a commitment to long-term cooperation and market expansion [2][4]. Agreement Overview - The agreement allows Keyuan Trading to exclusively promote the AC conjugate vaccine nationwide from 2024 to 2026, with a total promotion task of 4 million doses [4][5]. - A supplementary agreement has been signed to extend the original contract period from December 31, 2026, to December 31, 2029, while maintaining other core terms unchanged [5][6]. Impact on Company Performance - The signing of the agreement is not expected to have a significant impact on the company's current operating performance [3][7]. - The projected sales volume for the AC conjugate vaccine in 2024 is 252,000 doses, but there is uncertainty regarding the actual sales performance due to market conditions [7].

Core Viewpoint - JianKai Technology experienced significant trading activity on January 5, with a total of 12 block trades amounting to 550,600 shares and a total transaction value of 41.90 million yuan, reflecting a discount of 17.17% compared to the closing price of the day [2][3] Trading Activity Summary - The stock's closing price on January 5 was 91.88 yuan, marking an increase of 11.78% with a turnover rate of 3.71% and a total trading volume of 201 million yuan, while there was a net outflow of 711,900 yuan in main funds [2] - Over the past five days, the stock has risen by 11.44%, with a total net inflow of 2.36 million yuan [2] - In the last three months, there have been 31 block trades for the stock, with a cumulative transaction value of 91.63 million yuan [2] Margin Trading Data - The latest margin financing balance for the stock is 172 million yuan, which has increased by 3.52 million yuan over the past five days, representing a growth rate of 2.08% [2]

Core Viewpoint - Watson Bio (300142) is committed to enhancing communication and collaboration with global health organizations and overseas biopharmaceutical companies in the international market [1] Group 1: International Business Development - The company will adopt diversified cooperation models to continuously promote the registration and export of its products in overseas markets [1] - There is a focus on accelerating the construction of localized industrial projects abroad to create value for the company and its shareholders [1] Group 2: Product Development and Updates - Investors are encouraged to keep an eye on the company's announcements regarding the progress of international business and related product development [1]

Core Viewpoint - Watson Bio is committed to enhancing communication and collaboration with global health organizations and overseas biopharmaceutical companies in the international market [1] Group 1 - The company will adopt diversified cooperation models to continuously promote the registration and export of its products in overseas markets [1] - Watson Bio aims to accelerate the construction of localized industrial projects abroad [1] - The initiatives are designed to create value for the company and its shareholders [1]